Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants

Journal of Allergy and Clinical Immunology

Volumn 114, Issue 5, 2004, Pages 1183-1188

  Kaufmann, Roland ^a,f   Fölster Holst, Regina ^b   Höger, Peter ^c   Thaçi, Diamant ^a   Löffler, Helena ^d   Staab, Doris ^e   Bräutigam, Matthias ^d  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d NOVARTIS PHARMA GMBH   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

atopic eczema; dermatitis; infants; Pimecrolimus

Indexed keywords

PIMECROLIMUS;

ARTICLE; ASTHMA; ATOPIC DERMATITIS; BRONCHITIS; BURNING SENSATION; CAREGIVER; CHICKENPOX; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREAM; DERMATITIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; HERPES SIMPLEX; HUMAN; IMPETIGO; INFANCY; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN BURNING SENSATION; SKIN TOXICITY; SLEEP; SUPERINFECTION; SYMPTOM; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; OINTMENTS; TACROLIMUS;

EID: 7944234980     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2004.08.015     Document Type: Article

References (29)

1. L.F. Schultz The epidemiology of atopic dermatitis Monogr Allergy 31 1993 9 28
2. J. Kay, D.J. Gawkrodger, M.J. Mortimer, and A.G. Jaron The prevalence of childhood atopic eczema in a general population J Am Acad Dermatol 30 1994 35 39
3. N. Wadonda, J. Golding, and C. Kennedy Prevalence of atopic eczema in children between 0 and 30 months on Avon district Br J Dermatol 143 suppl 57 2000 33
4. J.M. Spergel, and A.S. Paller Atopic dermatitis and the atopic march J Allergy Clin Immunol 112 suppl 2003 S118 S127
5. M. Boguniewicz, L.F. Eichenfield, and T. Hultsch Current management of atopic dermatitis and interruption of the atopic march J Allergy Clin Immunol 112 suppl 2003 S140 S150
6. S.S. Raimer Managing pediatric atopic dermatitis Clin Pediatr (Phila) 39 2000 1 14
7. S. Gunther [Incidence and degree of unwanted adverse effects of corticoids in childhood: results of dermatological studies in children with chronic diseases in the age group of 1-15 years] Z Hautkr 51 1976 569 579
8. C.J. Hill, and A. Rostenberg Jr. Adverse effects from topical steroids Cutis 21 1978 624 628
9. C.J. McLean, R.F. Lobo, and D.J. Brazier Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment Lancet 345 1995 330
10. C. Queille, R. Pommarede, and J.H. Saurat Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood Pediatr Dermatol 1 1984 246 253
11. R. Ruiz-Maldonado, G. Zapata, T. Lourdes, and C. Robles Cushing's syndrome after topical application of corticosteroids Am J Dis Child 136 1982 274 275
12. H.H. Bode Dwarfism following long-term topical corticosteroid therapy JAMA 244 1980 813 814
13. J.G. Meingassner, M. Grassberger, H. Fahrngruber, H.D. Moore, H. Schuurman, and A. Stutz A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology Br J Dermatol 137 1997 568 576
14. T. Hultsch, K.D. Muller, J.G. Meingassner, M. Grassberger, R.E. Schopf, and J. Knop Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner Arch Dermatol Res 290 1998 501 507
15. M. Grassberger, T. Baumruker, A. Enz, P. Hiestand, T. Hultsch, and F. Kalthoff A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology Br J Dermatol 141 1999 264 273
16. T. Zuberbier, S.U. Chong, K. Grunow, S. Guhl, P. Welker, and M. Grassberger The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils J Allergy Clin Immunol 108 2001 275 280
17. C. Queille-Roussel, C. Paul, L. Duteil, M.C. Lefebvre, G. Rapatz, and M. Zagula The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study Br J Dermatol 144 2001 507 513
18. U. Wahn, J. Bos, M. Goodfield, R. Caputo, K. Papp, and A. Manjra Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children Pediatrics 110 2002 e2
19. A. Kapp, K. Papp, A. Bingham, R. Folster-Holst, J.P. Ortonne, and P.C. Potter Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug J Allergy Clin Immunol 110 2002 277 284
20. M. Meurer, R. Folster-Holst, G. Wozel, G. Weidinger, M. Junger, and M. Brautigam Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study Dermatology 205 2002 271 277
21. Administration UFaD Guidance for Industry. E6 good clinical practice: consolidated guidance Federal Register 62 1997 25691 25709
22. J.L. Seymour, B.H. Keswick, J.M. Hanifin, W.P. Jordan, and M.C. Milligan Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis J Am Acad Dermatol 17 1987 988 997
23. J.M. Hanifin, M. Thurston, M. Omoto, R. Cherill, S.J. Tofte, and M. Graeber The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group Exp Dermatol 10 2001 11 18
24. N. Barbier, C. Paul, T. Luger, R. Allen, Y. De Prost, and K. Papp Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% clinical program Br J Dermatol 150 2004 96 102
25. L.F. Eichenfield, A.W. Lucky, M. Boguniewicz, R.G. Langley, R. Cherill, and K. Marshall Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents J Am Acad Dermatol 46 2002 495 504
26. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis Dermatology 186 1993 23 31
27. B. Kunz, A.P. Oranje, L. Labreze, J.F. Stalder, J. Ring, and A. Taieb Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis Dermatology 195 1997 10 19
28. V.C. Ho, A. Gupta, R. Kaufmann, G. Todd, F. Vanaclocha, and R. Takaoka Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants J Pediatr 142 2003 155 162
29. P. Reid, and M.S. Lewis-Jones Sleep difficulties and their management in preschoolers with atopic eczema Clin Exp Dermatol 20 1995 38 41